Novartis Opens Radioligand Therapy Manufacturing Plant in US
Novartis, a leader in innovative medicines, has launched a 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California. The site marks an important step...
FDA Grants Approval for CAPLYTA for MDD Treatment in Adults
Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has granted approval for CAPLYTA (lumateperone) to be used as an adjunctive...
FDA Approves J&J’s DARZALEX FASPRO for HR-SMM in Adults
Johnson & Johnson said the U.S. Food and Drug Administration (FDA) has cleared DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for use as a single-agent treatment...
FDA Approves UCB’s KYGEVVI for Thymidine Kinase 2 Deficiency
UCB, a leading global biopharmaceutical company, has announced that KYGEVVI has received FDA approval for the treatment of adults and pediatric patients diagnosed with...
Lilly to Expand its Manufacturing Facility in Puerto Rico
Eli Lilly and Company has unveiled plans to invest more than $1.2 billion to expand and modernize its Lilly del Caribe manufacturing site in...
Lilly, NVIDIA Partner on AI Supercomputer for Drug Research
Eli Lilly and Company has revealed plans to construct what it calls the most powerful supercomputer ever built and operated by a pharmaceutical company,...
FDA Unveils Initiative for Faster Biosimilar Development
The U.S. Food and Drug Administration (FDA) has unveiled a major initiative aimed at cutting both the time and cost required to develop biosimilar...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...